Siemens Corporate Research spin-off and Speedus Corp. subsidiary, Zargis Medical Corp., announced Friday that it has received U.S. Food and Drug Administration clearance to market the new Signal X6(TM) device. The company also announced that seven Signal X6 devices have been delivered to the U.S. Army for deployment in six Department of Defense medical facilities.

Signal X6 technology records heart and lung sounds from six adhesive sensors. The recordings can be evaluated locally or, when a cardiac specialist is not immediately available, transmitted through the Internet for remote evaluation. This feature makes the noninvasive technology easy to use. The configuration of the Signal X6 provides a unique telemedicine resource in situations where evaluations could benefit from high fidelity multi-channel synchronous recordings.

Prototypes for Signal X6 were first developed with funding from the Telemedicine and Advanced Technology Research Center (TATRC), of the USAMRMC, through the AAMTI program. The AAMTI program provides funding to demonstrate technology and document the impact on cost, access and quality of care.

John Kallassy, Zargis’ CEO, stated, “As healthcare systems continue to demand improved outcomes with utilization of fewer resources, we believe that Signal X6 will provide cost-effective, high quality cardiac analysis in situations where it’s not practical for a patient to visit a specialist.”